A strategy of protease inhibitor (PI) mono-therapy with re-introduction of triple therapy in those who rebound has been shown to be a safe and effective treatment simplification approach for long-term management. We sought evidence for cerebrospinal fluid (CSF) virological escape in patients on long-term PI monotherapy.
Methods
We performed lumbar puncture in asymptomatic participants with suppressed plasma HIV RNA after 96 weeks on the PI monotherapy arm (PI-mono) of the PIVOT trial. We also report CSF HIV RNA concentration in trial participants who were investigated for neurological/ neurocognitive symptoms during the trial regardless of study arm allocation.
Results
All 11 asymptomatic participants on PI-mono who were tested had undetectable CSF HIV RNA at week 96. One of the three symptomatic participants on PI-mono had CSF HIV RNA of 1,895 copies/ml (undetectable in plasma) and neither of two symptomatic participants on triple therapy had CSF HIV RNA detected.
Conclusions
CSF virological escape appears rare in asymptomatic patients on PI monotherapy and may not warrant routine CSF monitoring, but patients with symptoms merit more concern.
References
1.
PatonN.I., StohrW., Arenas-PintoA.Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial.Lancet HIV2015; 2: e417–e426.
2.
MathisS., KhanlariB., PulidoF.Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis.PLoS One2011; 6: e22003.
3.
PulidoF., ArribasJ.R., DelgadoR.Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV.AIDS2008; 22: F1–F9.
4.
ArribasJ.R., HorbanA., GerstoftJ.The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml.AIDS2010; 24: 223–230.
5.
EdénA., FuchsD., HagbergL.HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment.J Infect Dis2010; 202: 1819–1825.
6.
RawsonT., MuirD., MackieN.E., GarveyL.J., EverittA., WinstonA.Factors associated with cerebrospinal fluid HIV RNA in HIV infected subjects undergoing lumbar puncture examination in a clinical setting.J Infect2012; 65: 239–245.
7.
PatonN.I., StohrW., OddershedeL.The Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy (PIVOT) trial: a randomised controlled trial of a protease inhibitor monotherapy strategy for long-term management of human immunodeficiency virus infection.Health Technol Assess2016; 20: 1–158.
8.
FerrettiF., BigoloniA., PasseriL.Cerebrospinal fluid analysis for HIV replication and biomarkers of immune activation and neurodegeneration in long-term atazanavir/ ritonavir monotherapy treated patients.Medicine (Baltimore)2016; 95: e4144.
9.
TiraboschiJ., HamzahL., TeagueA.The impact of switching from Atripla to darunavir/ritonavir monotherapy on neurocognition, quality of life, and sleep: results from a randomized controlled study.AIDS Res Hum Retroviruses2016; 32: 1198–1201.
10.
StöhrW., DunnD.T., Arenas-PintoA.Factors associated with virological rebound in HIV-infected patients receiving protease inhibitor monotherapy.AIDS2016; 30: 2617–2624.
11.
DelilleC.A., PruettS.T., MarconiV.C.Effect of protein binding on unbound atazanavir and darunavir cerebrospinal fluid concentrations.J Clin Pharmacol2014; 54: 1063–1071.
12.
GutmannC., CusiniA., GunthardH.F.Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir.AIDS2010; 24: 2347–2354.
13.
KahlertC., BregenzerA., GutmannC.Late treatment failures in cerebrospinal fluid in patients on long-term maintenance ART with ritonavir-boosted protease PI monotherapy.Infection2016; 44: 329–335.
14.
VernazzaP., DaneelS., SchifferV.The role of compartment penetration in PI-monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial.AIDS2007; 21: 1309–1315.
15.
SantosJ.R., LlibreJ.M., BravoI.Short communication: efficacy and safety of treatment simplification to lopinavir/ritonavir or darunavir/ritonavir monotherapy: a randomized clinical trial.AIDS Res Hum Retroviruses2016; 32: 452–455.
16.
EstébanezM., Stella-AscarizN., MingoranceJ.A comparative study of neurocognitively impaired patients receiving protease inhibitor monotherapy or triple-drug antiretroviral therapy.J Acquir Immune Defic Syndr2014; 67: 419–423.
17.
KatlamaC., ValantinM.A., Algarte-GeninM.Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136.AIDS2010; 24: 2365–2374.
18.
AntinoriA., ClarkeA., Svedhem-JohanssonV.Week 48 efficacy and central nervous system analysis of darunavir/ ritonavir monotherapy versus darunavir/ritonavir with two nucleoside analogues.AIDS2015; 29: 1811–1820.
19.
FerrettiF., GisslenM., CinqueP., PriceR.W.Cerebrospinal fluid HIV escape from antiretroviral therapy.Curr HIV/ AIDS Rep2015; 12: 280–288.
20.
HeatonR.K., CliffordD.B., FranklinD.R.Jr.HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study.Neurology2010; 75: 2087–2096.
21.
SimioniS., CavassiniM., AnnoniJ.M.Cognitive dysfunction in HIV patients despite long-standing suppression of viremia.AIDS2010; 24: 1243–1250.
22.
SacktorN., SkolaskyR.L., SeabergE.Prevalence of HIV-associated neurocognitive disorders in the Multicenter AIDS Cohort Study.Neurology2016; 86: 334–340.
